Spero Therapeutics Inc. (SPRO)
NASDAQ · Healthcare
Spero Therapeutics Inc. Operating Income 2016–2025
Spero Therapeutics Inc. annual/quarterly operating income history and growth rate from 2016 to 2026. Operating income (EBIT) is profit from core business operations, excluding interest and income taxes. It reflects the efficiency of a company's core operations.
- Spero Therapeutics Inc. operating income for the quarter ending March 31, 2026 was -7.5 M, a 48.83% decrease year-over-year.
- Spero Therapeutics Inc. operating income for the twelve months ending March 31, 2026 was -32.6 M, a 39.09% decrease year-over-year.
- Spero Therapeutics Inc. annual operating income for 2025 was 6.3 M, a 108.61% decrease from 2024.
- Spero Therapeutics Inc. annual operating income for 2024 was -73.4 M, a 441.52% decrease from 2023.
- Spero Therapeutics Inc. annual operating income for 2023 was 21.5 M, a 150.91% decrease from 2022.
- Spero Therapeutics Inc. annual operating income for 2022 was -42.2 M.
Operating Income
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Spero Therapeutics Inc. Operating Income — FAQ
Spero Therapeutics Inc. (SPRO) operating income over the last 10 years — annual and quarterly figures with year-over-year growth and charts.
What is Spero Therapeutics Inc.'s operating income?
Spero Therapeutics Inc. (SPRO) reported operating income of $6M for fiscal 2025.
Where can I see SPRO's operating income history?
The chart and table above show Spero Therapeutics Inc.'s operating income by year and by quarter, including the growth rate.